This website uses cookies to ensure you have the best experience. Learn more

Eli Lilly Essay

1676 words - 7 pages


Case Brief on

Eli Lilly: The Evista Project

4000-2000 BC – Ancient Egyptians developed compresses around Skull to stop migraines. 1876 – Eli Lilly founded in Indianapolis, Indiana by Colonel Eli Lilly. 1970s – Early research in Lilly on Serotonin. 1988 – Prozac launched to market 1991 – Serotonin “1f” receptor cloned by Lilly’s collaborator, Synaptic Pharmaceutical Corporation. CNS group starts screening serotonin like compounds from Lilly’s historical library 1992 – Glaxo launched sumatriptin (Imitrex) 1994 March/April “Hot” lead compound found from the screen with good fit at the serotonin 1f receptor Kaldor gives combinatorial chemistry ...view middle of the document...

This would approximately take 3 years to pass the test. Once the per-clinical was cleared the drugs were tested on the humans, which had to pass three phases for duration of 6 years. These three stages involve the safety trial, efficiency and the long term efficiency trial. Once the drug cleared it is registered for the FDA approval which will take another 2 to 3 years. On the whole the product to be commercialized it would take 12 to 13 years.

A Heavyweight team structure is a project management organizational structure that consists of specialized experts led by a project manager that engages members from different functions to relate to each other to improve products and processes that need to undergo major changes. The project manager usually a higher officer in the company is responsible for the work of all those involved in the project. There were five keys characteristics defined a heavyweight team at Lilly. First, the teams were each given a very clear business charter “to focus exclusively on the development of a single compound.” Second, each team was collocated and cross functional. Third, the teams were each led by a “heavyweight” project manager. Fourth, each team took responsibility for the sub-stance of the work, how the work was accomplished, and the ensuing results. Fifth, each team had two executive sponsors, one from LRL (Lilly Research Laboratories) and one from the business

group, who guided them and worked to resolve conflicts between the team and the rest of the Lilly organization. “Heavyweight” are the leaders in two respects. First, they are senior managers within the organization. Hence, in addition to having expertise and experience, they also wield significant organizational clout. Second, heavyweight leaders have primarily influence over the people working on the development effort and supervise their work directly through key functional people on the core teams. When managed effectively, heavyweight team offers improved communication, strong identification with and commitment to a project, and a focus on crossfunctional problem solving. Regarding the Eli Lilly, what compelled Watanabe, Executive VP of science and technology to implement the use of the heavyweight approach is that the company had an impact on revenues loosing $18 billion in market capitalization between 1991 and1995. He felt the need to halt the traditional approach to effectively run the organization.

What is your assessment of the performance of the two heavyweight project teams described in the case? What factors contributed most to these performance results? In the Pharmaceutical context how far back in the development process should heavyweight teams be deployed?

Two major successes resulted in the performance of the two heavyweight project teams described in the case that were not assigned to the traditional approach that Lilly used before for organizing development project. Watanabe announced the formation of two heavyweight...

Other Papers Like Eli Lilly

Cialis Case Analysis

4148 words - 17 pages market leader and only company garnering a 90% market share for ED. A company ICOS, a small biotech start-up wanted to get into the industry and eventually wanted to become a self-sufficient biotech company and acquire its own clinical development and marketing capabilities. ICOS was competent in R&D, but, not in marketing and bringing a drug to market through the FDA. In 1998, they strategically partnered with Eli Lilly and Company, the

Anxiety Disorders and Depression Treatment Market Expected to Reach USD 18.2 Billion Globally in 2020

1005 words - 5 pages growth of the market in Asia Pacific. Browse the full Press Release : The market displays intense competitive rivalry among existing players, as currently the market for antidepressant and anxiolytic drugs is highly fragmented comprising both large and small manufacturers. Major market players include AstraZeneca plc, Eli Lilly and Company

Case Study Merck Acquisition

1000 words - 4 pages have joined with PBMs. In 1995, the FTC challenged Eli Lilly and Company’s acquisition of PCS, another PBM, from the McKesson Corporation, alleging violation of the antitrust laws. At that time, the Commission pledged to monitor the industry carefully and cautioned that it might take future action if it concluded there were signs of anticompetitive conduct in the industry. Their investigation into the PBM industry has revealed that Merck’s

Advances in the Obesity Market at Researchmoz

1272 words - 6 pages 1: Glp-1 Analogues And Agonists.16 ones To Watch .17 liraglutide (novo Nordisk).17 waitin G In The Win Gs.18 exenatide (bristol-myers Squibb/eli Lilly).18 long Shots .19 tt-401 (eli Lilly/transition Therapeutics).19 zp2929 (zealand Pharma/boehringer Ingelheim).19 Advances in the Obesity Market zyog1 (zydus Cadila).19 approach 1: Anorexi Genic Pepti De Analo Gues An D Mo Dulators .20 drug Type Ii: Neuropeptide Modulators.20 ones To Watch

Becoming a Phamacist

1314 words - 6 pages companies out there for them to look into. One great place for research located in Indianapolis Indiana is Eli Lilly. They are a global pharmaceutical company with over 24 billion dollars in sales. Looking at the job website for Eli Lilly one will see it is filled with positions for research and development. Those opportunities are perfect for any PharmD that is interested in doing research. Looking at just about any hospital career website

Millennium Pharmaceuticals

1126 words - 5 pages Millennium as they decided to pursue research in cardiovascular, central nervous system, respiratory and oncology segments. Right way this investment paid off and additional alliances were made. This time alliances with Eli Lilly, Astra and Wyeth-Ayerst were formed. All these companies wanted work done in disciplines that Millennium had invested in with proceeds from Roche. These deals signed were even more lucrative for Millennium. Millennium

Economics for Managers

1120 words - 5 pages . TEMPORARY DISQUILIBRIUM THEORY OF PROFIT 3. MONOPOLY THEORY OF PROFIT 4. INNOVATION THEORY OF PROFIT 5. MANAGERIAL EFFICIENCY THEORY OF PROFIT Slide 7 What Went Right? What Went Wrong? • Eli Lilly (p. 16) a Pharmaceutical company » 12.3 on average to get a new drug approved » Patents on Lilly’s Prozac created monopoly power and profits for a widely used medication for depression. » As the patent began to expire, Lilly requested s patent

Strategic Pricing Proposal To Counter Generic Sildenafil

2427 words - 10 pages Wyeth, Paxil and Welbutrin XL from GlaxoSmithKline, and Cymbalta from Eli Lilly & Co. The demand for Zoloft was inelastic before patent expiration which allowed Pfizer to set a high price for the drug. Demand then became elastic when generics entered the market post-patent expiration. The below graphs display this change in demand elasticity for Zoloft. We expect this will be the same for Viagra. PAST AND CURRENT STATE

Seeds of Growth(Innovation & Technology Management)

2037 words - 9 pages sourcing strategies,” where suppliers link together to provide the benefits of single sourcing (with little of the downside). Insights and Transformation The sheer human intellectual connectivity of the Web can represent an incredible resource for firms. The key question is how can this be mobilized? Eli Lilly and Co. is exploring an interesting experiment called InnoCentive. Using the InnoCentive digital/networked consortium approach, Eli Lilly

Research on Osteoarthritis Pain - Pipeline Review, H2 2014

1537 words - 7 pages Ibuprofen And Methyl Salicylate 135 jun 03, 2013: Ampio Pharma Provides Update On Spring Trial Of Ampion For Treatment Of Osteoarthritis Of Knee 136 mar 15, 2013: Bone Medical Re-affirms Strategy To Pursue Oral Calcitonin Program 137 nov 07, 2012: Eli Lilly Receives Health Canada Approval For Cymbalta For Management Of Osteoarthritis Knee Pain 137 nov 06, 2012: Array Biopharma To Present Phase Ii Results Of Arry-797 At 2012 American College Of

Business Decision Making

1078 words - 5 pages Income (Bn USD)/EPS Share of Revenue from Drugs 2.2 /$1.27 36.9% 15 2.2 /$1.10 65.5% US 14.6 1.5 /$0.58 87.8% Roche EU 12.1 2.5 /$3.20 69.4% Merck US 11.7 1.7 /$0.56 93.7% Abbott US 9.5 1.2 /$1.03 69.1% Sanofi-Aventis EU 8.5 2.0 /$0.60 95.5% GlaxoSmithKline UK 7.4 2.0 /$0.80 84.2% AstraZeneca UK 7.4 2.2 /$1.50 100% Eli

Related Essays

Eli Lilly Essay

982 words - 4 pages Question1: Did Eli Lilly pursue the right strategy to enter the Indian market? In 1993 Eli Lilly, one of the leading pharmaceutical firms in the USA, started a joint venture in India with the leading Indian company Ranbaxy. The decision was dictated by the conditions of the US market and opportunities of the Indian market. Costlier manufacturing practices due to strict governmental control, soaring prices in 1990s, invasion of cheap generics to

Eli Lily Essay

603 words - 3 pages Eli Lilly in India : Rethinking the Joint Venture Strategy Pharmaceutical companies spend more than 20% of their sales on research and development (R &D). Patents for product ( for 20 years) and process were essential means by which a firm protected its proprietary knowledge and they could command higher prices for their products. Many multinational pharmaceutical firm subsidiaries in India imported drugs from their country of origin and made a

Joint Venture Agreements Essay

1117 words - 5 pages Eli Lilly in India Case Study BUS 545 – Global Business Management May 31, 2015 Andrew Juarez Professor Barnett   Executive Summary This report provides an analysis and evaluation of the case study “Eli Lilly in India”. The general overview of the case study is the discussion of the Joint Venture agreements between two parties. Eli Lilly a reputable pharmaceutical company entered the Indian market in a joint venture agreement with

Pfizer (Pfe) Financial Analysis

1838 words - 8 pages | 31.30 | 23.25 | 9.24 | Allergan PLC | – | – | 111.88 | Bristol-Myers Squibb Co. | 49.80 | 35.01 | 30.56 | Eli Lilly & Co. | 33.06 | 13.88 | 14.99 | GlaxoSmithKline PLC | 27.28 | 16.59 | 16.21 | Johnson & Johnson | 17.15 | 18.72 | 19.64 | Merck & Co. Inc. | 13.94 | 37.83 | 20.94 | P/E Ratio, Sector | | | | Pharmaceuticals | 23.56 | 17.73 | 16.56 | P/E Ratio, Industry | | | | Health Care | 23.50 | 20.07